Trump Slams FDA Regulations In Joint Session Of Congress
US president hit on his sentiments of faster drug approval times and deregulation, signaling FDA could be in for period of sustained criticism.
You may also be interested in...
State of the Union address touts FDA's record number of approvals, but also endorses right to try proposals and renews president's call for lower drug prices.
FDA is addressing regulatory reform as part of President Trump's "two-for-one" executive order, and seeks industry comments to supplement the effort.
US FDA’s decision to accept Amicus’ migalastat NDA without a new study is the latest sign of the positive climate for rare disease drugs at FDA. But will it be remembered as a turning point?